|
Patent landscape, scope, and claims: |
Scope and claim analysis for US Patent 9,730,890 (formoterol stable nebulizable aqueous composition): what is covered, where infringement risk sits, and how the patent landscape is likely structured for generics and follow-on products
US Patent 9,730,890 claims a formoterol (free base) aqueous pharmaceutical composition defined by (i) concentration ranges, (ii) stability and shelf-life performance, (iii) optionality of nebulization, (iv) polarity/protic solvent scope, and (v) specific excipient classes for tonicity adjustment and buffers, with quantified buffer concentration and ionic strength embodiments. The estate scope is strongest where a competing product is formoterol free base in water at ~0.08 to 128 µg/mL, maintains long-term storage stability meeting the specific performance thresholds, and uses buffer/tonicity systems within the claimed ranges and lists.
What patents protect US 9,730,890 claims 1-20, and how broad are the independent and dependent claims?
Core protected subject matter (Claim 1, independent)
Claim 1 is the primary infringement anchor. It covers:
- A pharmaceutical composition comprising
- formoterol or a thereof
- in a pharmacologically suitable fluid that is stable during long term storage
- where the fluid comprises water
- with formoterol free base concentration of about 0.08 µg/mL to about 128 µg/mL.
- Functional stability language: “stable during long term storage” is supported by performance claims (Claims 2-3) that quantify shelf-life and residual API.
Key scope implications
- API form: “formoterol, or a thereof” plus the phrase formoterol free base concentration indicates the claim focuses on free base equivalent concentration even if the formulation uses a salt form that converts to or yields a free base concentration during assay.
- Medium: “fluid comprises water” means fully aqueous or aqueous-dominant systems are within scope. The claim does not exclude co-solvents or buffers in Claim 1, but those details are pushed into dependent claims.
- Concentration span: The range 0.08–128 µg/mL is broad enough to cover multiple nebulizer strengths if converted to µg/mL equivalents, but it can still be engineered around by selecting a concentration outside the endpoints (depending on how “about” is construed).
Dependent claim expansion
- Claim 2 and 3 add specific shelf-life and residual API thresholds.
- Claim 4 adds nebulized (method/product-use concept).
- Claims 5-6 broaden solvent system: polar solvent, protic solvent.
- Claims 7-9 add tonicity adjusting agent and a long enumerated list, with a narrower dependent embodiment (sodium chloride).
- Claims 10-18 add buffer systems, select buffer identities, and buffer concentration ranges and point values.
- Claim 19-20 add ionic strength limits.
Claim-by-claim infringement map (coverage and practical design-around levers)
| Claim |
What it adds |
Practical impact for a competitor |
| 1 |
Stable aqueous formoterol composition; free base concentration 0.08–128 µg/mL |
Broad base coverage. Concentration and aqueous stability are the first pass “yes/no” gates. |
| 2 |
Shelf-life: >1 month at 25°C usage time and ≥1 year at 5°C storage |
Requires matching stability data, directly relevant for Paragraph IV-style arguments and evidence submissions. |
| 3 |
>80% of initial formoterol after 1 month @25°C and 1 year @5°C |
Establishes a quantitative residual threshold. |
| 4 |
Composition that has been nebulized |
Tends to function as product-use; still can be relevant to how labels and instructions are drafted. |
| 5-6 |
Polar solvent; protic solvent |
Helps catch co-solvent systems. Likely limits design-around via “non-polar” or “aprotic only” systems, but Claim 1 already requires water. |
| 7-9 |
Tonicity adjusting agent and enumerated list; includes sodium chloride specifically |
If competitor uses a tonicity agent outside the list, or no tonicity agent, they may reduce claim coverage (subject to doctrine of equivalents / “or a thereof” arguments). |
| 10-13 |
Buffer requirement; then specific buffers; includes citrate buffer |
Captures common buffer systems used for pH and stability. |
| 14-18 |
Citrate buffer concentration windows: 0.01–150 mM, then 1–50 mM, then 1–20 mM, then exact points 20 mM and 5 mM |
Creates narrow embodiments that are easiest to avoid by selecting buffer concentration outside the recited windows, assuming claim validity/enforcement tracks these embodiments as written. |
| 19-20 |
Ionic strength: 0–0.4 and 0.05–0.16 |
Adds a parameter that can be tuned by adjusting salt/buffer. Most competitor formulations will land inside some band; careful formulation can target out-of-range ionic strength. |
How does the claimed concentration range (0.08–128 µg/mL) drive infringement risk?
The most important numeric constraint in Claim 1 is:
- Formoterol free base concentration about 0.08 µg/mL to about 128 µg/mL.
Concentration engineerable or not?
- For nebulizer products, the “strength” is often labeled in µg/mL or mg per mL. If a competitor’s strength is substantially below 0.08 µg/mL or above 128 µg/mL, Claim 1 may not read on the formulation.
- “About” creates tolerance, so an exact boundary is rarely safe. However, a large shift is the typical litigation-safe strategy: moving well outside the claimed band rather than testing near endpoints.
Salt vs free base equivalence
The claim text explicitly tracks free base concentration, even though commercial formoterol often appears as formoterol fumarate in labels. That alignment raises two consequences:
- Competitors must assess whether assay and formulation specs report free base equivalents and how those map to claim construction.
- If a generic relies on a different salt form, the assayed “free base equivalent” could still land inside the claimed concentration window.
What do the stability claims require, and how do they affect a generic’s bioequivalence-only strategy?
Claims 2 and 3 embed performance requirements that are frequently decisive in formulation patent litigation:
- Claim 2: estimated shelf-life
- >1 month usage time at 25°C
- and ≥1 year storage time at 5°C.
- Claim 3: residual formoterol
- >80% of initial formoterol after 1 month @25°C
- and 1 year @5°C.
Stability evidence is the central battleground
Because these claims are quantitative, a challenger cannot rely on pharmacokinetic sameness alone. The “same drug, different container” narrative usually fails when the patent is framed around formulation stability metrics.
Litigant behavior typically mirrors these thresholds
- Patent holders push stability protocols that match the claim timepoints/temperature conditions.
- Generics push stability studies showing either out-of-threshold residuals are avoided, or that the tested composition falls outside the claim scope by excipient choice, concentration, buffer/ionic strength, or effective “free base” equivalence.
Does “nebulized” (Claim 4) create standalone infringement exposure?
Claim 4: “composition of Claim 1 that has been nebulized.”
In practice, this clause matters most if:
- the product is marketed and used as a nebulizer solution, and
- the formulation patent is asserted in a context where use is demonstrable (e.g., label instructions, real-world use, or clinical administration).
For pure “composition” infringement, the composition still must meet Claim 1. Claim 4 can be used to reinforce the intended application and to narrow defenses around “not a nebulizer solution” if labeling is inconsistent.
What solvent and excipient scope is actually claimed?
Polar/protic solvent scope (Claims 5-6)
Claim 5 requires a polar pharmacologically suitable fluid; Claim 6 specifies protic solvent. Since Claim 1 already requires water, the practical coverage is “aqueous protic media,” capturing typical formulation solvents.
Tonicity adjusting agent list is a major coverage lever (Claims 7-9)
Claim 7 requires tonicity adjusting agent. Claim 8 enumerates a very large list (ammonium salts, acids/sugars/alcohols, chlorides/phosphates/sulfates, urea, etc.). Claim 9 narrows to sodium chloride.
Implications
- If a competitor uses a tonicity agent not in the enumerated list, they can argue non-infringement for Claims 7-9.
- If they use sodium chloride (common), the narrow dependent claim becomes a direct hit if other Claim 1 elements are satisfied.
Buffer scope (Claims 10-18) is both broad (family) and narrow (named systems + concentration)
Claim 10: buffer is required.
Claim 11: enumerated buffers.
Claim 12: buffer comprises citric acid/phosphate, acetate, citrate, or phosphate.
Claim 13: buffer is citrate buffer.
Claims 14-18: citrate buffer concentration windows including multiple tiers and discrete points (20 mM, 5 mM).
Implications
- Most realistic formoterol nebulizer solutions use citrate or phosphate buffer. If they do, then Claims 10-13 are likely implicated.
- Ionic strength and buffer concentration give formulation scientists room to design around by selecting buffers and concentrations outside the recited windows, though “about” again creates tolerance.
How does ionic strength (Claims 19-20) constrain formulation design?
- Claim 19: ionic strength about 0 to about 0.4.
- Claim 20: ionic strength about 0.05 to about 0.16.
These bands are broad; most buffered aqueous solutions will fall somewhere within or near these windows depending on salt and buffer loading.
Practical reading
- Claim 19 is a very wide inclusive band that can cover many conventional formulations.
- Claim 20 is a narrower sub-band that can be used to target typical strengths if competitor formulations cluster around common ionic strengths.
What is the expected US patent landscape around US 9,730,890-style formulation claims?
Even without additional documents in your prompt, the claim structure is characteristic of a formulation patent estate that typically appears in clusters:
Likely “adjacent” patent families in the same product space
- Aqueous nebulizer solutions for beta-agonists (formoterol, arformoterol, other LABAs) with:
- specific free base equivalents and concentration ranges,
- buffer systems (citrate/phosphate),
- tonicity agents (salts, sugars, polyols),
- and stability performance over refrigerated and ambient conditions.
- Methods of preventing degradation in aqueous solutions via buffer chemistry and ionic strength control.
- Container/administration stability patents sometimes follow, but Claim 1 here is composition-focused, so the main estate is likely excipient-and-stability driven.
Typical claim dependencies in such estates
- Independent claims cover a broad composition frame.
- Second/third claims establish storage stability metrics.
- Dependent claims narrow into:
- tonicity agent enumerations,
- buffer families,
- and quantitative concentrations/ionic strength.
Where competitors typically find risk
- If a generic copies the general composition design (water + citrate buffer + common tonicity agent like sodium chloride + conventional ionic strength), it can land inside the claim funnel.
- If it changes one axis (different buffer identity, different concentration, no tonicity agent, different ionic strength), risk can drop, but only if it exits Claim 1’s base concentration and the remaining performance requirements.
Key legal interpretation checkpoints that affect claim scope
“Formoterol, or a thereof” and free base equivalents
This wording expands coverage beyond a single chemical form. For infringement analyses, mapping:
- what formoterol form is used (salt vs base),
- how the formulation assays report concentrations,
- and whether the claim “free base concentration” is met
is typically essential.
Functional stability terms: “stable during long term storage” plus quantified shelf-life
Courts and experts usually treat “stable during long term storage” as needing correlation to measurable stability. Claims 2-3 supply that bridge.
“About” for numeric ranges
“About” reduces the ability to design around by micro-adjustment. A meaningful shift away from endpoints (buffer concentrations, ionic strength, concentration ranges) is usually needed.
Commercial and regulatory positioning: what generic or follow-on products face based on these claims?
A competitor seeking to launch a formoterol nebulizer solution in the US typically confronts three practical tasks:
-
Match or avoid the Claim 1 composition envelope
- water-based fluid
- free base equivalent concentration within 0.08–128 µg/mL
- stability consistent with “stable during long term storage.”
-
Avoid failing Claims 2-3 stability thresholds
- If stability testing at 25°C (1 month usage time) and 5°C (1 year storage) demonstrates residual >80%, it strengthens infringement posture.
- If the competitor can credibly show residual below the threshold or failed shelf-life windows, it weakens enforcement for those dependent claims.
-
Tune excipient choices relative to dependent claim lists and parameters
- tonicity agent: avoid enumerated agents, especially sodium chloride if other elements are present.
- buffer: avoid citrate buffer or its recited concentrations if feasible.
- ionic strength: tune outside the narrower band where practical.
How strong is the patent estate for typical formoterol nebulizer solution designs?
Based on the structure of Claims 1-20, the estate is strongest where:
- the formulation is aqueous, with formoterol free base equivalent in the claimed µg/mL band,
- it uses standard buffers (citrate) and common tonicity agents (often sodium chloride or equivalent),
- and it achieves conventional stability through buffering and controlled ionic strength.
The estate is weaker only where competitors can:
- move out of the concentration range,
- substitute buffer systems and concentrations outside the recited windows,
- omit or swap tonicity agents outside the enumerated list,
- and create stability outcomes that do not meet the residual and shelf-life thresholds.
What cannot be concluded from the claims alone (and is therefore excluded here)
This analysis does not provide:
- claim construction rulings,
- prior art mappings,
- prosecution history outcomes,
- or the Orange Book / FDA listing status,
because those require patent metadata, bibliographic details, and FDA database records not present in the prompt.
Key Takeaways
- US 9,730,890 centers on water-based formoterol free base aqueous formulations with concentration 0.08–128 µg/mL and a stability premise.
- Claims 2-3 are the most litigation-relevant: they require measured shelf-life and residual API under 25°C (1 month) and 5°C (1 year) conditions.
- Dependent claims create a second infringement layer through citrate buffer identity and concentration bands, tonicity agents (including sodium chloride), and ionic strength ranges.
- Design-around options exist mainly by moving formulation out of the free base concentration band, selecting buffer systems and concentrations outside the recited ranges, and tuning ionic strength and stability performance away from the >80% residual / shelf-life thresholds.
FAQs
- How can a competitor avoid infringement of a formoterol free base concentration claim if the drug is formulated as a salt?
- Do citrate buffer concentration sub-ranges (1–20 mM vs exact 5 mM or 20 mM) meaningfully reduce enforcement risk in typical nebulizer formulations?
- Can choosing a tonicity agent outside the long enumerated list eliminate infringement for dependent Claims 7-9?
- What formulation changes most often shift ionic strength outside 0.05–0.16 without harming formoterol stability?
- How do the 25°C “usage time” and 5°C “storage time” stability timepoints influence the design of stability protocols in litigation?
References
- United States Patent No. 9,730,890. Claims 1-20 provided in user prompt.
More… ↓
⤷ Start Trial
|
